Monday, May 11, 2026

Netanyahu's 8th Front

HOW TO CURE EVERYTHING: risk-rewards will massively change once Cell Cinema scales I keep coming back to one question: what becomes worth attempting when biology becomes easier to read? Most conversations about AI and drug discovery are still stuck on generation. ............. But the deeper shift happens when the biological feedback loop becomes fast and information-rich enough that those generated ideas can be corrected by reality. ................

This is one reason software compounds so quickly.

................ In biology, the feedback loop has been slow, expensive, destructive, and often indirect. It involves: perturbing a system, waiting, stop experiment, stain it, sequence it, image it, or run an endpoint assay, and then reconstruct what you think happened. Sometimes that works. Sometimes the most important part of the biology happened in between the timepoints, in a cell state you did not measure, through a compensatory pathway you did not expect, or in a form of toxicity that only becomes obvious when the system is watched over time. ........ Cell Cinema is what changes when that feedback loop starts to look more like a movie and less like an autopsy. ............... The real point is that living cells move through states, and many of the most important drug effects are not static. ................ If you only ask one question at one timepoint, you get one kind of answer. If you watch many dimensions of the same living system over time, you get Cell Cinema. .............

Drug discovery has always had a strange risk-reward shape.

.................. The reward for being right is enormous. A successful drug can change the standard of care for a disease, create a generational company, and alter the lives of millions of people. But the risk of being wrong is also enormous, because you often find out late. You can spend years building conviction around a target, molecule, indication, and mechanism, only to discover in humans that the biology did not translate, the drug was toxic, the effect was too weak, or the disease was not being modulated in the way your model implied. .................... When the cost of being wrong is catastrophic, rational people cluster around validated biology, known modalities, precedent, and mechanisms that have already survived some contact with the clinic. The industry says it wants novelty, but structurally it punishes novelty whenever the measurement layer cannot make that novelty legible. Only one thing can change this: readout. ................. The first wave is simple derisking. This is the least glamorous part and probably the most commercially important place to begin. If a drug has toxicity, off-target effects, or an ugly cellular phenotype, I want us to find that earlier. About 60-70% of a 90% failure rate in drug discovery are clustered around tox and off-target effects. ..................... Cell Cinema sees them as (1) live, and (2) high-dimensional vectors. This matters. Cells do not simply jump from healthy to dead, instead they often are benefitted by evolution, and compensate, adapt, fail, recover, or enter intermediate states. A destructive endpoint assay can miss those trajectories because it collapses the process into a final measurement. A living readout can show the path where a lot of the truth is; in biology, this truth is simply too high-dimensional for anything other than a GPU. ................. the problem starts scaling. Intelligence, too cheap to meter. That scale creates the highest impact: behavioral. ............ Moving truth earlier in the development timeline is one of the most powerful things you can do in drug discovery, because late truth destroys companies and early truth compounds. Once THAT starts happening, people become willing to take better risks. ....................

Giving eyes to the blind.

..................... If there is no precedent, there is no easy prior. If there is no easy prior, every committee, investor, pharma BD team, and internal champion has to decide whether the evidence is strong enough to overcome the discomfort of the unknown. .................. This is the point where the economics start to change in a very, very non-obvious way. Better readout does not just reduce bad bets. It increases the expected value of bold bets. If the probability of success rises while the reward remains high, then entire categories of programs that used to look irrational begin to look rational. ..............

Readout brings in the AGI of biology.

.............. intelligence becomes coupled to experimentation tightly enough that the system learns from biology at a speed and resolution we have never had before. ................. The next experiment is better because the last experiment was richer. ............. Over time, the system becomes better at asking biology questions.This is the third wave, and it is the biggest one. At that point, drug discovery becomes less like asking “does this molecule bind this target?” and more like asking “what state is this cell in, what state should it be in, and what intervention moves it there without creating unacceptable damage elsewhere?” That is a fundamentally different search problem. ..................... an increasingly predictive model of cellular response connected to a scalable system for observing actual living biology is a software-like revolution. ................. The world is going to generate more candidate drugs, more modalities, more edits, more combinations, and more mechanistic hypotheses than it can evaluate using the old stack. Someone just had to build the system that tells the world which of those ideas are real. The reward will shift toward whoever owns that evidence. ................... In the previous era, much of the value sat with companies that had clinical development capacity, regulatory expertise, capital, manufacturing, and commercial reach. But as generation becomes cheaper, validation becomes more valuable. If molecule design becomes more commoditized, then the hard-to-recreate asset is the trusted biological readout. ......................... Importantly, this HAS TO compound through society. Suddenly, humanity is more willing to try. More diseases become economically addressable, the valley of death improves and the frontier of medicine moves because the frontier of evidence moved first. ................ the real unlock of lowering uncertainty lies in the places where uncertainty changes decisions. ............. If drug discovery became easy overnight, then eventually the rewards would compress. Successful drugs would become less scarce, some categories would commoditize, and the economics of therapeutics would look different. That is not where we are. We are nowhere near saturation. Most diseases are not solved, and biology is still barely understood. The world still has far more unmet need than credible therapeutic programs. .............. if Cell Cinema, Cleopatra, and related downstream technologies lower the risk of making drugs while the rewards remain high, the immediate effect is not commoditization. The immediate effect is MORE, BETTER, AND MORE AMBITIOUS ATTEMPTS.

at No comments:
Labels:
Subscribe to: Posts (Atom)